Ono Pharmaceutical has set a net-zero greenhouse-gas emissions target. The company aims to achieve this by 2050. To achieve this goal, Ono Pharmaceutical has aligned its operations with the Paris Agreement and the United Nations’ Sustainable Development Goals. The company has also joined the RE100 initiative and is committed to sourcing 100% renewable electricity by 2050.
Ono Pharmaceutical has implemented several measures to reduce its carbon footprint. The company has installed solar panels at its headquarters in Osaka, Japan, which generate approximately 10% of the electricity consumed at the site. In addition, Ono Pharmaceutical has implemented energy-saving measures such as LED lighting and air conditioning systems that use natural refrigerants.
Ono Pharmaceutical is also working with suppliers to reduce emissions throughout its supply chain. The company has established a Green Procurement Policy that requires suppliers to comply with environmental regulations and reduce their environmental impact.
Ono Pharmaceutical is committed to reducing emissions from transportation. The company is promoting the use of electric vehicles (EVs) and has installed EV charging stations at its facilities.
Ono Pharmaceutical’s efforts to reduce greenhouse-gas emissions are part of its commitment to sustainability. The company recognizes that climate change is a global issue that requires collective action.
by Ono Pharmaceutical
Pharmaceuticals Adlumiz is a medicine that contains the active substance anamorelin hydrochloride.
Supplies to Every ContinentDesigned in JapanMade in Japan
by Ono Pharmaceutical
Certification
FDA CCP
Manufacturer
by Ono Pharmaceutical
Pharmaceuticals This medication is used to treat high blood pressure in people with a certain adrenal gland tumor (pheochromocytoma).
Supplies to Every ContinentDesigned in JapanMade in Japan
by Ono Pharmaceutical
Certification
FDA CCP
Manufacturer
by Ono Pharmaceutical
Pharmaceuticals BRAFTOVI + MEKTOVI is a combination therapy for adults with BRAF+ (V600E or V600K) melanoma that has spread (metastatic) or that cannot be removed by surgery. BRAFTOVI should not be used to treat people with wild-type BRAF melanoma.
Supplies to Every ContinentDesigned in JapanMade in Japan
by Ono Pharmaceutical
Certification
FDA CCP
Manufacturer
Get new company profiles every week!